openPR Logo
Press release

Depression - Pipeline Review & Swot Analysis by key Manufacturers Atai Life Sciences AG, Avanir Pharmaceuticals, Avicanna, Axsome Therapeutics

07-02-2020 02:01 PM CET | Health & Medicine

Press release from: HTF Market Intelligence Consulting Private Limited

Depression

Depression

A new independent 668 page research with title 'Depression - Pipeline Review, H1 2020' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, South America, Asia & Pacific, Europe & MEA (Middle East and Africa) and important players/vendors such as Acadia Pharmaceuticals Inc, Adamed Sp zoo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aision Biotechnologies Inc, Alkermes Plc etc. With n-number of tables and figures examining the Depression Market., the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2026.

Get customization & check discount for report @https://www.htfmarketreport.com/request-discount/2582842-depression-pipeline-review-1

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2020, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request a sample report @https://www.htfmarketreport.com/sample-report/2582842-depression-pipeline-review-1

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 7 molecules, respectively.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Place a Purchase Order for this Market Study (Single User License) at@https://www.htfmarketreport.com/buy-now?format=1&report=2582842
Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

Acadia Pharmaceuticals Inc, Adamed Sp zoo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aision Biotechnologies Inc, Alkermes Plc, Allergan Plc, Amorsa Therapeutics Inc, Anavex Life Sciences Corp, Angelini Group, Antheia Inc, Asulon Therapeutics Inc, Atai Life Sciences AG, Avanir Pharmaceuticals Inc, Avicanna Inc, Axsome Therapeutics Inc, Azevan Pharmaceuticals Inc, Baergic Bio Inc, Beloteca Inc, Bionomics Ltd, BioStem Technologies Inc, BioXcel Therapeutics Inc and others

Table of Contents
Introduction
Depression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
AppendixList of Tables
Number of Products

....Continued

View Detailed Table of Content @https://www.htfmarketreport.com/reports/2582842-depression-pipeline-review-1

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Depression - Pipeline Review & Swot Analysis by key Manufacturers Atai Life Sciences AG, Avanir Pharmaceuticals, Avicanna, Axsome Therapeutics here

News-ID: 2083610 • Views:

More Releases from HTF Market Intelligence Consulting Private Limited

Viral Detection Market Current Scenario and Future Prospects (2024-2030) |
Viral Detection Market Current Scenario and Future Prospects (2024-2030) |
The latest study released on the Global Viral Detection Market by HTF MI evaluates market size, trend, and forecast to 2030. The Viral Detection market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players in
Fraud Detection Software Market Insights into Competitive Landscape and Market Forecast 2024-2032
Fraud Detection Software Market Insights into Competitive Landscape and Market F …
The Insurance Fraud Detection Software Market has witnessed continuous growth in the past few years and is projected to grow at a good pace during the forecast period of 2024-2030. The exploration provides a 360° view and insights, highlighting major outcomes of Insurance Fraud Detection Software industry. These insights help business decision-makers to formulate better business plans and make informed decisions to improve profitability. Additionally, the study helps venture or
Solar Powered ATM Market: A Comprehensive Study Explores Huge Growth in Future | Euronet Worldwide, Fujitsu, Zenom Solar Power
Solar Powered ATM Market: A Comprehensive Study Explores Huge Growth in Future | …
The Solar Powered ATM Market has witnessed continuous growth in the past few years and is projected to grow at a good pace during the forecast period of 2024-2030. The exploration provides a 360° view and insights, highlighting major outcomes of Solar Powered ATM industry. These insights help business decision-makers to formulate better business plans and make informed decisions to improve profitability. Additionally, the study helps venture or emerging players
Sports Marketing Service Market: Ready To Fly on high Growth Trends | Sportfive, Infront Sports & Media, SportsCloud
Sports Marketing Service Market: Ready To Fly on high Growth Trends | Sportfive, …
The latest study released on the Global Sports Marketing Service Market by HTF MI Research evaluates market size, trend, and forecast to 2030. The Sports Marketing Service market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the

All 5 Releases


More Releases for Depression

Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned. Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%